Drugs / CATCH T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05103631 | Jun 2021 → Jan 2025 overdue | Wilms tumor, hepatocellular carcinoma, liposarcoma, rhabdoid tumor +3 | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CATCH T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05103631 ↗ |
| Action | Deplete | “The mixture of GPC3-CAR and IL15 killed tumor cells better in the laboratory when compared with CAR T cells that did not have IL 15.” NCT05103631 ↗ |
| Modality | Cell therapy | “This study will test T cells genetically engineered with a GPC3-CAR and IL15 (CATCH T cells) in patients with GPC3-positive solid tumors.” NCT05103631 ↗ |
| Route | Other | “the cells will be thawed and injected into the patient over 5 to 10 minutes.” NCT05103631 ↗ |